Abstract:Pulmonary fibrosis (PF) is a type of interstitial pneumonia with complex etiology and high mortality, characterized by progressive scarring of the alveolar interstitium and myofibroblastic lesions. Recently, there has been growing appreciation of the importance of long non-coding RNAs (lncRNAs) in organ fibrosis. The aim of this study was to investigate the role of lncRNAs in lung fibrosis. We used a qRT-PCR assay to identify dysregulated lncRNAs in the lungs of mice with experimental, bleomycin (BLM)-induced pulmonary fibrosis, and a series of molecular assays to assess the role of the novel lncRNA NONMMUT060091, designated as pulmonary fibrosis inhibitor (PFI), which was significantly downregulated in lung fibrosis. Functionally, knockdown of endogenous PFI by smart silencer promoted proliferation, differentiation, and extracellular matrix (ECM) deposition in primary mouse lung fibroblasts (MLFs). In contrast, overexpression of PFI partially abrogated TGF-β1-induced fibrogenesis both in MLFs and in the human fetal lung fibroblast MRC-5 cells. Similarly, PFI overexpression attenuated BLM-induced pulmonary fibrosis compared with wild type (WT) mice. Mechanistically, using chromatin isolation by RNA purification-mass spectrometry (ChIRP-MS) and an RNA pull-down assay, PFI was found to directly bind Serine/arginine-rich splicing factor 1 (SRSF1), and to repress its expression and pro-fibrotic activity. Furthermore, silencing of SRSF1 inhibited TGF-β1-induced proliferation, differentiation, and ECM deposition in MRC-5 cells by limiting the formation of the EDA+Fn1 splicing isoform; whereas forced expression of SRSF1 by intratracheal injection of adeno-associated virus 5 (AAV5) ablated the anti-fibrotic effect of PFI in BLM-treated mice. Overall, these data reveal that PFI mitigated pulmonary fibrosis through negative regulation of the expression and activity of SRSF1 to decrease the formation of the EDA+Fn1 splicing isoform, and suggest that PFI and SRSF1 may serve as potential targets for the treatment of lung fibrosis.

PAI-1 Interaction with Sortilin Related Receptor-1 is Required for Lung Fibrosis

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

PAI-1: A New Target for Controlling Lung-Cell Senescence and Fibrosis?

PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

Critical Roles of PAI-1 in Lipopolysaccharide-Induced Acute Lung Injury.

The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis

Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis

S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function

Urokinase Plasminogen Activator Overexpression Reverses Established Lung Fibrosis

S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

Plasminogen Activator Inhibitor 1, Fibroblast Apoptosis Resistance, and Aging-Related Susceptibility to Lung Fibrosis

Inhibition of PAI‐1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer‐associated fibroblasts

Gene therapy with AAV9‐SGPL1 in an animal model of lung fibrosis

Plasminogen Activator Inhibitor Type-1 Deficiency Exaggerates Lps-Induced Acute Lung Injury Through Enhancing Toll-Like Receptor 4 Signaling Pathway

Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-Β1 Expression in Macrophage

Small leucine zipper protein negatively regulates liver fibrosis by suppressing the expression of plasminogen activator inhibitor-1

Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human Fibroblasts

TGF-β1–induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis

The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1

Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis